MedDataX Logo

Investigate the Effect of Ezetimibe, Simvastatin, and Omega 3- Fatty Acids on Dyslipidemia Patients: a Pharmacokinetics Based Study

NCT ID: NCT05080140

Last Updated: 2021-10-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

3 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-06-01

Study Completion Date

2022-03-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized controlled pharmacokinetic based study will be carried out on patients with both sexes and various ages, plasma triglycerides levels, clinical health disorders and using different agents for treatment of their hyperlipidemia in order to access the optimal drug therapy with best cost effectiveness in the elderly cases under investigation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperlipidemia; Mixed

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Simvastatin

No interventions assigned to this group

Ezetimibe

Ezetimibe 10mg

Intervention Type DRUG

Effect of ezetimibe on hyperlipidemia on patients with diabetes mellites

Omega -3 fatty acids-

No interventions assigned to this group

Simvastatin+ Ezetimibe

Ezetimibe 10mg

Intervention Type DRUG

Effect of ezetimibe on hyperlipidemia on patients with diabetes mellites

Simvastain + ezetimibe + omega

Ezetimibe 10mg

Intervention Type DRUG

Effect of ezetimibe on hyperlipidemia on patients with diabetes mellites

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ezetimibe 10mg

Effect of ezetimibe on hyperlipidemia on patients with diabetes mellites

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients of dyslipidemia with high triglyceride level (200 to 499 mg/100 ml).
* Total cholesterol level more than 200 mg/100 ml
* Male and female
* Age 35 - 70 years

Exclusion Criteria

* \- Hypersensitivity of drugs
* Liver toxicity
* -Patients suffering from renal dysfunction
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Misr University for Science and Technology

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Yasmine Farouk

Teacher Assistant - clinical pharmacy department

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Misr University for science and technology

Giza, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1606YAS141008

Identifier Type: -

Identifier Source: org_study_id